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Summary:
Seventy-two patients with non-Hodgkin’s lymphoma
were evaluated for the presence of molecular markers
(IgH, bcl-1, bcl-2 rearrangement) on bone marrow, at
diagnosis and after PBSCT, and on harvests in order to
find a possible predictive role of minimal residual dis-
ease on treatment outcome. At diagnosis, 41 (59%) out
of 69 available bone marrows showed molecular
involvement. Fifty-six percent of leukaphereses were
involved, mainly indolent lymphoma (P = 0.001) or
advanced disease (P = 0.01). Ex vivo purging cleared
only one stem collection out of 31 PCR-positive leukaph-
ereses. Aggressive lymphomas showed both a longer
overall survival (OS) (P = 0.03) and relapse-free survival
RFS (P = 0.02) when transplanted with unpurged stem
cells, whereas indolent NHL survival was not influenced
by ex vivo purging. Twenty out of 26 samples taken dur-
ing follow-up had bone marrow involvement at diag-
nosis. Of these, 15 cleared their bone marrow; both OS
and RFS were significantly longer in the PCR-negative
cases (P = 0.05 and P = 0.005). At 1 year after PBSCT,
75% of patients were PCR negative, with 50% molecu-
lar remissions; the relapse rate was 55% for patients
still PCR positive vs 29% for those who were PCR
negative. Thus, after high-dose chemotherapy, close
molecular monitoring of MRD using qualitative PCR
techniques seems to represent a reliable prognostic
indicator.
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High-dose chemotherapy followed by hematopoietic stem
cell transplantation has significantly improved the prog-
nosis of non-Hodgkin’s lymphomas (NHL).1 Several clini-
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cal parameters, such as the International Prognostic Index
(IPI),2 extra-nodal manifestations3 and time to relapse,4
have been proven to be the most statistically significant
independent variables predicting outcome. Nevertheless,
relapse is frequent, indicating incomplete eradication by
conditioning regimens or the presence of residual neoplastic
cells in the reinfused graft. Therefore, the identification of
parameters other than the previously mentioned clinical
ones is needed. In this respect, various molecular markers,
ie IgH, Bcl 2, Bcl 1 and TCR rearrangements, are now
available for both molecular diagnosis and for the evalu-
ation of minimal residual disease in patients with NHL.
Although these molecular assays are sufficiently sensitive
and specific, their predictive role in minimal residual dis-
ease (MRD) detection is still controversial. Moreover,
although many ex vivo and in vivo purging techniques have
been developed to eliminate residual malignant cells from
the inoculum, a clear clinical advantage has not been
definitely established.
Rates of contamination of harvested progenitors range
from 56%5 to 100%,6 depending on histology, treatment
protocols, purging procedures and molecular assays. At
stem cell mobilization after ex vivo purging, 62% of
patients with aggressive lymphomas achieved molecular
remission and a higher continuous remission rate was
observed in those patients who received PCR-negative pro-
genitors.7 Similarly, in indolent lymphomas, several studies
have reported an increase in molecular remission rates from
40% up to 93% after in vivo purging by anti-CD20 mono-
clonal antibody.8 Furthermore, the role of contaminated
harvests in terms of future relapse has been demonstrated
in patients with both follicular6 and mantle cell NHL.9 The
effect upon outcome of an uncontaminated graft has also
been studied in indolent lymphomas, where a complete
remission rate of 38% was found in the group of patients
receiving PCR-positive progenitors vs 100% remission in
patients transplanted with no molecular evidence of malig-
nant cells.5 Finally, follicular lymphoma cases achieving
and maintaining molecular response experienced a longer
failure-free survival (FFS) as compared to those who either
reverted back to PCR positivity or never achieved a
molecular response.10
In the present paper, we evaluated 72 patients for the
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prognostic impact on patient outcome of lymphoma-
associated molecular markers at diagnosis and at the time
of stem cell collection. The role of in vitro purging was
also evaluated in a subset of patients with NHL.
Patients and methods
Eligibility and therapeutic schedule
Seventy-two histologically confirmed B cell NHL adult
patients, classified according to the Revised European
American Classification (REAL)11 and included in various
GISL (Gruppo Italiano per lo Studio dei Linfomi) proto-
cols, were retrospectively evaluated. Cases were selected
on the basis of availability of mobilized peripheral blood
and bone marrow cryopreserved at diagnosis. This GISL
study was designed to investigate whether (1) high-dose
therapy and autologous transplantation increases molecular
remission rate and (2) the quality of molecular remission
independently correlates with PFS. Clinical data were ana-
lyzed in December 2000. Indolent lymphomas were also
included in an ongoing protocol with the aim of evaluating
the role of autotransplant even in this clinical setting.
At the beginning of therapy, all patients underwent stag-
ing procedures, including history, physical examination,
hematology and serum chemistry profile, total body com-
puterized tomography, bone marrow aspiration and biopsy.
All patients had measurable or evaluable disease, an ECOG
performance status 2, white blood cell (WBC) count 2
 109/l, platelets 100  109/l and adequate heart, liver
and kidney function. Clinical characteristics are listed in
Table 1. Histology was defined according to the REAL
classification in 62 patients. Among the 36 indolent lym-
phomas, 21 were classified as follicular and five as mantle
cell. Of the remaining 26 cases with aggressive disease, 24
Table 1 Characteristics of the non-Hodgkin’s lymphoma patients
studied
No (%)
Total No. of patients 72
Evaluable for outcome 60
Evaluable for clinical features 62
Sex 27 M/45 F
Median age/range 42/18–61
Histology
Indolent 36 (58)
Aggessive 26 (42)
Stage
I–II 18 (29)
III–IV 44 (71)
IPI
Low/low–intermediate 53 (85)
High–intermediate/high 9 (15)
Median follow-up (months)/range 57/6–114
Harvests (done) 66 (92)
PBSCT (done) 50 (81)
Median follow up from PBSCT (months) 46
Disease status
CR/PR 38/8 (63/13)
Progression–relapse 7 (12)
Deaths 7 (12)
were diffuse large cell lymphomas (DLCL). At diagnosis,
the majority of the patients (71%) were at an advanced dis-
ease stage and 85% had a low or low–intermediate Inter-
national Prognostic Index (IPI).
All patients received CHOP or CHOP-like treatment as
first-line therapy before starting the high-dose protocol.
According to the protocol of Gianni et al,12 patients
received CTX 7 g/m2 i.v. either at the beginning or at the
end of the following sequence of drugs (VP-16 2 g/m2 i.v.,
MTX 8 g/m2 i.v. and VCR 2 mg i.v.), based on the absence
or presence of histologically-proven bone marrow infil-
tration, respectively. Patients received G-CSF 5 g/m2 s.c.
and CD34+ cells were monitored daily by flow cytometry
as the WBC started to increase after aplasia, with a target
yield of 5.0  106/kg CD34+ selected cells. One or two
harvests from each patient was evaluated for minimal
residual disease by molecular assay.
Conditioning included mitoxantrone 60 mg/m2 i.v. on
day −5 and melphalan 180 mg/m2 on day −4. In 31 cases
(15 aggressive and 16 indolent), ex vivo purging was per-
formed on leukapheresis products using anti-CD20 anti-
body (negative selection) incubation followed by anti-
CD34 immune adsorption (positive selection).
Complete remission (CR) was defined on the basis of the
resolution of all symptoms and signs of lymphoma and
bone marrow clearing; partial remission (PR) required
50% decrease of lesions; patients who did not achieve a
CR or PR were considered resistant.
Statistical methods
All calculations were performed using the SPSS for win-
dows, release 9.0, 1999. Time to relapse or progression was
analyzed by the Kaplan–Meier method. Difference in PFS
between prognostic groups was evaluated on univariate
analysis by the log-rank test. Comparisons of clinical
response data by individual prognostic variables were
performed using the Fisher’s exact test.
Molecular assays
PCR analyses were performed on bone marrow and leuka-
pheretic samples. Mononuclear cells were isolated by frac-
tionation on Ficoll/Hypaque (Axis-Schield, Oslo, Norway)
gradient; high molecular weight DNA was extracted and suit-
able aliquots were utilized for PCR tests after spectrophoto-
metric quantitative evaluation.
Two consensus primers were designed for the VH-DH-
JH region of the immunoglobulin heavy chain gene (IgH),
as previously described;13–14 the downstream primer was 5
labeled with 6-FAM fluorochrome.
The sequences were as follows: VH region primer (third
framework region): 5-ACA CGG CYS TGT ATT ACT
GT-3; VH region primer (second framework region): 5-
TGG [A/G]T CCG [C/A]C AG[G/C] C[T/C][T/C] CNG G-
3; JH consensus external primer: 5-ACC TGA GGA GAC
GGT GAC CA-3; JH consensus inner primer: 5-ACC
AGG GTC CCT TGG CCC CA-3.
PCR fragment length ranged from 65 to 130 bp for the
CDR3 and from 240 to 280 bp for the FR2. PCRs were
performed in a Gene Amp PCR System 2400 (Applied
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25 l, containing 1.5 units Taq DNA Polymerase (Eurobio,
Les Ulis, France), 67 mmol/l Tris-HCl (pH 8.8), 16 mmol/l
(NH4)2SO4, 0.01% Tween 20, MgCl2 1.5 mm, 200 mol/l
dNTPs, 0.4 mol/l of each primer and 1 g of DNA. Every
PCR procedure included distilled water instead of DNA as
a negative control and DNA carrying monoclonal IgH
rearrangement as a positive control.
Each individual cycle consisted of denaturation at 95°C
30 s, annealing at 55°C 30 s for first round PCR or 58°C
30 s for second-round PCR and a final extension at 72°C
of 30 s. These cycles were repeated 30 times, preceded by
2 min of denaturation at 95°C and followed by 5 min of
chain elongation at 72°C.
In order to amplify BCL2-IgH rearrangement, nested
PCR reactions were performed in a final volume of 25 l
using 1 g of DNA, 0.4 mol/l of oligonucleotide primers,
200 mol/l each of dNTPs, MgCl2 2 mm and 1.5 U Taq
polymerase (Eurobio) in the 1 × PCR buffer (67 mmol/l
Tris-HCl, pH 8.8, 16 mmol/l (NH4)2SO4, 0.01% Tween
20).
The first round of PCR was performed for 25 cycles and
the second for 30 cycles; primers for MBR and MCR detec-
tion and reaction conditions were previously described by
Gribben et al,15 employing an inner JH primer 6-FAM
labeled.
In order to amplify BCL1-JH rearrangement, PCR reac-
tions were performed in a final volume of 25 l using 1
g of DNA, 0.4 mol/l of oligonucleotide primers, 200
mol/l each of dNTPs, 2 mm MgCl2 and 1.5 U Taq poly-
merase (Eurobio) in the 1 × PCR buffer (67 mmol/l Tris-
HCl, pH 8.8, 16 mmol/l (NH4)2SO4, 0.01% Tween 20).
Each amplification included a consensus IgH consensus
primer, as reported above, and a forward primer, as
described by Molot et al.16
PCR-amplified products were resolved by 2.5% agarose
gel and then by capillary electrophoresis. Samples were
prepared for analysis by mixing 0.8 l of PCR products
with 15 l of deionized formamide (Sigma, St Louis, MO,
USA) and 0.5 l Gene Scan 500 Tamra-labeled internal
standard (Applied Biosystem). This mixture was denatured
at 95°C for 2 min and then quickly cooled on ice. Capillary
electrophoresis and fluorescence detection with a virtual
filter C was performed on ABI Prism 310 Genetic Analyzer
(Applied Biosystem).
Runs were executed with the module GS STR POP 4 (1
ml) C with 10-s and 15 kV injection and run voltage, 60°C
constant temperature, 24 min run time, using polymer POP
4 and the running buffer Genetic analyzer 1 × (Applied
Biosystem).
Genescan 2.1 software was then used to analyze the PCR
products, with accurate sizing and quantification of the peak
areas. This allows accurate prediction of the equivalence
point of PCR products from competitor and target mol-
ecules. The sensitivity of molecular assays resulted in
10−4/10−5.
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Results
Clinical outcome
Seventy-two patients were enrolled in this study and 60
were evaluable for outcome. Overall response was seen in
77%, with 63% complete remissions. Clinical responses
were not significantly correlated with age ( or50 years),
sex, histology (indolent or aggressive), IPI (low/low–inter-
mediate or high/high-intermediate), stage ( or  III),
molecular status at diagnosis, harvest contamination or
molecular status after transplant (data not shown).
Fifty-three patients (88%) remain alive at a median fol-
low-up of 57 months. No treatment-related deaths occurred;
seven patients died, six relapsed and one because of an
infectious complication after more than 100 days from the
graft. Overall survival (OS) of the entire patient population
was 87% (95% CI, 80–107) with a significant advantage in
favor of the indolent group (96% vs 74%, P = 0.06); over-
all, patients showed a relapse-free survival (RFS) of 72%
(95% CI, 55–85). Although not significant, RFS was longer
in patients with aggressive disease (73% vs 62%).
Molecular results
Bone marrow samples were available for molecular analy-
sis from 69 patients at diagnosis; in 62 cases the histology
was defined according to the REAL classification. Twenty-
eight patients were PCR-negative and 41 (59%) showed a
clonal IgH rearrangement; 16 out of 21 follicular and 10
out of 24 DLCL cases showed a bcl2/JH rearrangement;
bcl1/JH rearrangement was found in 3/5 mantle cell lym-
phomas. Out of the remaining 12 cases, eight were classi-
fied as lymphoplasmocytic lymphomas, two as marginal
zone NHL, one as Burkitt, one as CLL. PCR positivity was
more frequent in the indolent than in the aggressive group
(68% vs 40%) (P = 0.02) and was significantly associated
with an advanced stage of neoplasia (P = 0.04), while no
significant correlation was found with age, sex or IPI. Mol-
ecular bone marrow involvement at diagnosis failed to
show any significant impact on either OS and RFS.
Out of 66 evaluable harvest products, 37 (56%) were
contaminated on PCR assay, 25 in the indolent and 12 in
the aggressive group. Again, PCR positivity was signifi-
cantly associated with indolent lymphoma (P = 0.001) and
with advanced disease stage (P = 0.01). Of note, lym-
phoma-free harvests did not give any clinical advantage in
terms of relapse rate, OS or RFS.
Harvests from 34 cases with PCR-positive bone marrow
were evaluated (Table 2). Twenty-eight harvests were con-
taminated, while five indolent and one aggressive lym-
phoma (18%) were PCR-negative. Of 26 bone marrows
PCR negative at diagnosis, eight (31%) contained contami-
nated stem cell precursors on mobilization (P  0.01).
The power of ex vivo purging procedures was assessed
in 31 PCR-positive leukapheresis products (16 indolent and
15 aggressive lymphomas). Twenty-two were at an
advanced disease stage. Only one stem cell collection was
cleared by purging, and ex vivo purging failed to remove
the malignant cells from contaminated apheresis products
in 3/8 cases with a negative bone marrow at diagnosis.
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Table 2 Clinical outcome and PCR monitoring of the 26 patients also molecularly tested after PBSCT
Patient Histology Molecular status Molecular status Molecular status Molecular status Molecular status Clinical
No. (according at diagnosis of harvests 3 months after 6 months after 12 months after outcome
to REAL) PBSCT PBSCT PBSCT
1 indolent PCR positive PCR positive PCR positive relapse
2 indolent PCR positive PCR positive PCR negative remission
3 indolent PCR positive PCR positive PCR negative PCR negative PCR negative remission
4 indolent PCR positive PCR positive PCR negative PCR negative PCR negative remission
5 indolent PCR positive PCR positive PCR negative PCR negative PCR negative remission
6 indolent PCR positive PCR positive PCR positive relapse
7 indolent PCR positive PCR positive PCR positive PCR negative PCR positive relapse
8 indolent PCR positive PCR positive PCR negative PCR positive PCR positive remission
9 indolent PCR positive PCR positive PCR negative remission
10 indolent PCR positive PCR positive PCR negative relapse
11 indolent PCR positive PCR positive PCR negative remission
12 indolent PCR positive PCR positive PCR negative remission
13 aggressive PCR positive PCR positive PCR positive PCR negative remission
14 aggressive PCR positive PCR positive PCR positive remission
15 aggressive PCR positive PCR positive PCR negative PCR negative relapse
16 aggressive PCR negative PCR negative PCR negative PCR negative remission
17 aggressive PCR negative PCR negative PCR negative relapse
18 aggressive PCR positive PCR positive PCR positive relapse
19 aggressive PCR positive PCR positive PCR positive PCR positive PCR negative remission
20 indolent PCR positive PCR positive PCR positive PCR positive PCR negative remission
21 indolent PCR positive PCR positive PCR negative PCR negative remission
22 indolent PCR positive PCR positive PCR negative PCR negative PCR negative remission
23 aggressive PCR negative PCR negative PCR negative remission
24 aggressive PCR negative PCR negative PCR negative remission
25 indolent PCR negative PCR negative PCR negative remission
26 aggressive PCR negative PCR negative PCR positive relapse
Bone marrow samples, available at 3 (26 cases), 6 (8
cases) and 12 months (12 cases) after transplant, underwent
molecular analysis during follow-up after PBSCT. Twenty
out of all 26 cases had bone marrow involvement at diag-
nosis. Molecular bone marrow remission was achieved in
12 cases (60%) after 3 months from transplant, including
eight cases that had received contaminated precursors. Two
other cases achieved molecular remission at 6 months;
thereafter, one of them reverted to PCR positivity and then
relapsed. One year from transplant, 15 (75%) patients with
molecular involvement of the bone marrow were PCR
negative. Fifty percent of patients transplanted with con-
taminated stem cells achieved molecular bone marrow
remission, independent of bone marrow PCR status at
diagnosis.
Molecular remission status after transplantation did not
significantly correlate with histology, age, sex, IPI, or dis-
ease stage. The relapse rate of patients still PCR positive
after transplantation was higher as compared to that seen
with PCR-negative patients (55% vs 29%), but the differ-
ence was not statistically significant (P = 0.23).
Figure 1 shows the influence of bone marrow PCR posi-
tivity after transplantation on OS. In fact, median OS was
85 months in the PCR-positive cases and it was not achi-
eved in the PCR-negative ones (P = 0.05). Similarly, RFS
(Figure 2) was significantly longer for PCR-negative cases
(median RFS not reached vs 21 months in the PCR-positive
group, P = 0.005).
Regardless of the efficacy of the procedure, 26% of
patients who received a purged apheresis product relapsed
vs 39% transplanted with unpurged precursors (P = 0.12).
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Figure 1 Overall survival of non-Hodgkin’s lymphoma patients receiv-
ing a blood stem cell harvest according to molecular status achieved after
PBSCT: the median was 85 months for patients still PCR positive vs a
median not achieved for PCR-negative patients (P = 0.05).
For the entire series, a trend for longer OS (P = 0.07) was
observed in patients transplanted with unpurged apheresis
products. In particular, 98% of unpurged cases were still
alive at 50 months as compared to 70% of cases trans-
planted with purged precursors (Figure 3). As far as RFS
is concerned, no statistical difference was observed
between the two groups (80% vs 58%, Figure 4). We ana-
lyzed the role of purging on OS and RFS in the aggressive
and indolent cases separately. Aggressive lymphomas
showed both a longer OS (P = 0.03, Figure 5) and RFS (P
= 0.02, Figure 6) when transplanted with unpurged stem
cells, whereas indolent NHL survival was not influenced
by ex vivo purging.
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Figure 2 Relapse-free survival of non-Hodgkin’s lymphoma patients
receiving a blood stem cell harvest according to molecular status achieved
after PBSCT: the median was 21 months for patients still PCR positive
vs a median not achieved for PCR-negative patients (P = 0.005).
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Figure 3 Overall survival of non-Hodgkin’s lymphoma patients receiv-
ing a blood stem cell harvest according to ex vivo purging procedure: 50-
month OS was 98% for patients reinfused with unpurged precursors vs
70% for patients receiving purged stem cells (P = 0.07).
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Figure 4 Relapse-free survival of non-Hodgkin’s lymphoma patients
receiving a blood stem cell harvest according to ex vivo purging procedure:
50-month RFS was 80% for patients reinfused with unpurged precursors
vs 58% for patients receiving purged stem cells (P = 0.32).
Discussion
Molecular evaluation of MRD in patients with NHL at
diagnosis and during several treatment phases has repeat-
edly been suggested to be a possible predictor of clinical
outcome. Bone marrow samples at diagnosis, harvest pro-
ducts and bone marrows during follow-up after high-dose
chemotherapy have been assessed for MRD in a series of
patients with aggressive and indolent NHL, with the aim
of evaluating the efficacy of ex vivo purging and the clinical
relevance of molecular MRD assessment at diagnosis and
after PBSCT.
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Figure 5 Overall survival of patients with aggressive NHL according to
the ex vivo purging procedure: the median was 40 months for patients
reinfused with purged precursors vs 84 months for those engrafted with
unpurged cells (P = 0.03).
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Figure 6 Relapse-free survival of patients with aggressive NHL accord-
ing to the ex vivo purging procedure: median was 33 months for patients
reinfused with purged precursors vs 72 months for those engrafted with
unpurged cells (P = 0.02).
In the entire series, OS and RFS were 87% and 72%,
respectively. In particular, RFS appeared advantageous for
aggressive histologies, in accordance with the situation
described in the literature.17,18
As expected, indolent histology and advanced disease
stage were significantly associated with molecular bone
marrow involvement at diagnosis and contaminated apher-
esis products. Patients with bone marrow involvement were
more likely to have contaminated stem cell harvests,
whereas lack of malignant bone marrow cells at diagnosis
was significantly associated with lymphoma-free harvests.
Nevertheless, 18% of PCR-positive cases harvested PCR-
negative progenitors and 31% of patients with PCR-nega-
tive marrow harvested PCR-positive peripheral blood stem
cells, indicating that the molecular status of the bone mar-
row could not be unequivocally used as a convenient pre-
dictor of tumor-free leukapheresis products. These data are
in accordance with those observed by Magni et al8 who
found that 44% of their patients with indolent NHL, who
were peripheral blood PCR, negative just before mobiliz-
ation, harvested contaminated precursors.
The appearance of contaminated precursors can be
explained either by their having been mobilized from
residual peripheral masses or for technical reasons. In our
series, lack of correlation between quality of remission and
molecular status of the harvest may be explained by the
high sensitivity of the molecular detection method
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employed in this study, and one could argue that the higher
concentration of residual neoplastic cells or the reduction
in lymphocytic polyclonal background observed in the
harvests might justify the finding of a high rate of PCR
positivity.
Whether ex vivo purging procedures are of clinical rel-
evance in either indolent or aggressive NHL is still a matter
of debate. In this regard, the European Blood and Marrow
Transplant Registry (EBMTR) reported a slightly longer 5-
year OS for patients who received purged marrow as com-
pared to that of patients receiving unmanipulated stem cells
(54% vs 48%), without differences in progression-free sur-
vival.19 In a series of 116 relapsed follicular lymphoma
patients with contaminated aphereses, the Dana Farber Can-
cer Institute reported 42% of molecular remissions after ex
vivo purging. The relapse risk for patients transplanted with
contaminated precursors was 11.7 times higher than that of
patients receiving PCR-negative grafts. The 8-year FFS in
purged patients was 19% for the patients whose bone mar-
row remained PCR positive vs 83% for patients receiving
PCR-negative bone marrow.20 Other studies demonstrated
a molecular remission rate ranging from 14% to 83%.18,21,22
Therefore, in vitro purging in autologous transplantation for
NHL should be further investigated. In our series, we
observed 18% of molecular remissions after ex vivo purging
procedures. Relapse rates were 26% and 39% for patients
receiving purged and unpurged aphereses, respectively.
In our series, in addition to the B cell-negative selection,
CD34-positive purging was performed. The expected bene-
fits of this procedure are related to the removal of tumor
cells lacking CD34 expression. However, the delay in T
lymphocyte recovery after CD34+ transplantation may
adversely contribute to clinical outcome. In fact, although
grafts were depleted of several logs by purging, a trend for
longer survival for patients receiving unpurged harvests
was found. This result seems to be more significant in
patients with aggressive lymphoma. However, these data
should be confirmed in a larger cohort of patients. Overall,
the feeling is that MRD status of the harvest should not be
considered the only clinico–biological variable to influence
both rate and duration of response. New, recently published
in vivo monoclonal antibody purging approaches indicate
that disease eradication may be more easily achieved than
by ex vivo purging8 methods.
The finding that molecular remission after PBSCT was
achieved in 75% of patients with molecular bone marrow
involvement at diagnosis and in 50% of cases transplanted
with contaminated progenitors suggests that transplantation
per se, through reducing residual disease offers a key
advantage in improving the clinical outcome of NHL
patients. This is in line with a recent report dealing with
follicular lymphomas, in which the risk of disease pro-
gression was 19.2 times higher for non-transplanted as
compared to transplanted patients.22
The role of MRD after PBSCT has also been studied.
Voso et al3 reported a relapse rate 4.5 times higher in fol-
licular lymphomas PCR positive after transplantation than
in negative cases. Similarly, the Dana Farber Cancer Insti-
tute20 reported that 36/39 cases PCR positive after BMT
relapsed. These data are in line with our results, demon-
strating a significantly longer RFS and OS for patients
achieving molecular remission after PBSCT. Thus, after
high-dose chemotherapy, close molecular monitoring of
MRD using qualitative PCR technique seems to represent
a reliable prognostic indicator.
In the near future, quantitative, rather than qualitative
assays for the evaluation of MRD may provide further
prognostic information in patients with NHL.
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